Jeffrey C. Davis, MD

Hip, Joint Replacement, Knee, Shoulder, Workers' Compensation

Request an Appointment

(205) 939-3699

Patient Ratings

4.8 Star review based on 225 patient ratings

Rate Dr. Davis

Biography

Hide Full Bio

Jeffrey C. Davis, MD I Robotic Hip & Knee Replacement & Hip Resurfacing Specialist

Three Decades of Experience. A Lifetime of Compassionate Care.

Jeffrey C. Davis, MD, is a board-certified orthopaedic surgeon specializing in robotic-assisted hip and knee replacement surgery, hip resurfacing and complex joint reconstruction.

For nearly three decades, he has helped thousands of patients overcome pain, restore mobility and return to the activities that matter most to them.

Recognized as one of Alabama’s leading joint replacement surgeons, Dr. Davis has built his practice on three enduring principles—experience, compassion and trust. As the longest-tenured orthopaedic surgeon at Andrews Sports Medicine & Orthopaedic Center, he has spent more than 30 years caring for generations of patients and their families while earning a reputation for exceptional surgical outcomes and personalized care.

Dr. Davis believes joint replacement surgery is about far more than replacing a damaged joint—it’s about restoring quality of life. Whether helping a grandparent play with their grandchildren, returning an injured worker to the job they love or enabling an active adult to resume golfing, hiking or traveling without pain, his goal remains the same: helping every patient confidently return to life without limitations.

Known for his thoughtful and compassionate approach, Dr. Davis takes time to understand each patient’s goals and develops individualized treatment plans tailored to their unique needs. Patients frequently describe him as caring, approachable and genuinely invested in their recovery. When requested, he often offers to pray with his patients before surgery—a reflection of the compassion, humility and faith that have guided his practice throughout his career.

Born in Decatur, Alabama, Dr. Davis moved to Atlanta at the age of seven and developed a lifelong passion for athletics. He attended the Georgia Institute of Technology, where he played football for three years before a knee injury ended his collegiate career—an experience that would ultimately inspire his pursuit of orthopaedic surgery.

Following his undergraduate education at Georgia Tech, Dr. Davis earned an Air Force scholarship to attend the Medical College of Georgia, where he received his medical degree. He completed his orthopaedic surgery residency at the renowned Campbell Clinic in Memphis, Tennessee—one of the nation’s premier orthopaedic training programs. Following residency, he proudly served as an orthopaedic surgeon in the United States Air Force, achieving the rank of Major and receiving the Air Force Achievement Medal for distinguished service.

In 1995, Dr. Davis relocated to Birmingham to join Dr. James R. Andrews and the Alabama Sports Medicine & Orthopaedic Center, now Andrews Sports Medicine. For more than three decades, he has remained committed to helping patients regain their independence, restore their mobility and improve their quality of life.

A pioneer in robotic-assisted joint replacement surgery, Dr. Davis was one of the first orthopaedic surgeons in Birmingham to perform robotic-assisted hip and knee replacement using Stryker’s Mako Robotic-Arm Assisted Technology. Since adopting the technology in 2017, he has performed nearly 2,500 robotic-assisted procedures, making him one of Alabama’s most experienced Mako surgeons. By combining advanced three-dimensional surgical planning with robotic precision, Dr. Davis personalizes every procedure to each patient’s unique anatomy to optimize implant positioning, improve joint function and support faster recovery with outstanding long-term outcomes.

Dr. Davis is also recognized as one of the region’s leading experts in hip resurfacing surgery and has established the largest hip resurfacing practice in the region. Since 2008, he has performed more than 600 hip resurfacing procedures with excellent patient satisfaction and long-term outcomes. Designed for carefully selected younger, active patients, hip resurfacing preserves more native bone than traditional hip replacement while allowing many individuals to safely return to high levels of physical activity following surgery.

In addition to caring for active adults and retirees, Dr. Davis has extensive experience treating patients with workplace injuries and performs one of the highest volumes of workers’ compensation joint replacement procedures in Alabama. He understands the physical, emotional and financial challenges that accompany these injuries and is committed to helping patients safely return to productive, active lives whenever possible.

Whether performing a robotic-assisted total knee replacement, restoring mobility through total hip replacement surgery or helping an active patient determine if hip resurfacing is the right option, Dr. Davis remains committed to delivering the highest level of orthopaedic care with compassion, precision and integrity.

For nearly three decades, patients have trusted Dr. Davis not only for his surgical expertise, but also for the genuine relationships he builds with those he serves. His greatest accomplishment isn’t measured by the number of procedures he has performed—it’s measured by the thousands of patients whose lives have been changed through restored movement, renewed confidence and a return to the activities they love.

Expertise & Specialties

Robotic-Assisted Total Hip Replacement
Robotic-Assisted Total Knee Replacement
Hip Resurfacing Surgery
Partial Knee Replacement
Arthritis Treatment & Joint Preservation
Workers’ Compensation Orthopaedic Care
Complex Hip & Knee Reconstruction
Minimally Invasive Joint Replacement Surgery

Medical Training & Education

View Education

Team Members

Hide All Team

Katie Beckham, PA-C View Bio

Comeback Stories

From Combat Injury to Coaching Again
A Hip Replacement Comeback:
Stephen overcame years of chronic pain with bi-lateral hip replacement, restoring his ability to move, coach, and live fully again.
Learn More

Stephen Schmidt | Huntsville, AL
Dr. Jeffrey Davis’ Victory Over COVID-19

Celebrating the strength, determination, and faith that carried him through one of life’s toughest battles.
Learn More

Victory Over COVID-19: Jeffrey C. Davis, MD Comeback Story | Birmingham, AL
Going into 2024, I never imagined needing two hip replacements. Years of running caught up with me, and osteoarthritis made everyday movement painful. With the help of Dr. Rachel Henderson and Dr. Jeffery Davis at Andrews Sports Medicine, I had both hips replaced—and now I’m on the road to making my comeback.
Learn More

Jamie Trimble | HOOVER, AL
It all started back in 2014, when I was living overseas in China at the time. One day my hip started bothering me. It continued to get worse and by Fall of that year, I could barely walk. I moved back to Birmingham around that time and knew that Andrews Sports Medicine was the best in the business.
Learn More

Shawn Bunch | Birmingham, AL
Living in the Montgomery, AL area, it can be a long drive to Andrews Sports Medicine in Birmingham. However, the drive is definitely worth the time. Dr. Jeffrey Davis and Dr. Charles Carnel are both extremely professional and knowledgeable while still having the ability to truly sympathize with their patient’s situation. The staff are all so kind and helpful, and everyone in the office is just outstanding.
Learn More

Valari Lagrone | Millbrook, AL

View All Dr. Davis Comeback Stories

Certifications Research Memberships

American Board of Orthopaedic Surgery, Board Certified

“An Active Comparator-Controlled, Parallel-Group, 1-Year, Double-Blind Study, Conducted Under In-House Blinding Conditions, to Assess the Safety and Efficacy of MK-0966 Versus Diclofenac Sodium in Patients With Osteoarthritis of the Knee of Hip”, Merck & Co., Inc., 1996

“A Double-Blind Comparison of the Efficacy and Safety of Extended Outpatient Treatment with Subcutaneous Normiflo^TMVS. Placebo for the Prevention of Venous Thromboembolism in Patients After Hip or Knee Replacement Surgery” Wyeth-Ayest, 1996.

“Relative Analgesic Efficacy and Safety of Oxycodone HCL 1.0 mg/Ibuprofen 400 mg, Oxycodone HCL 5 mg/Ibuprofen 400 mg, and Ibuprofen 400 mg Alone in Post Orthopedic Surgical Pain”, Forest Laboratories, 1997.

“A Placebo and Active Comparator-Controlled, Parallel-Group, 6 Week, Double Blind Study, Conducted Under In-House Blinding Conditions, to Assess the Safety and Efficacy of MK-0966 Versus Ibuprofen in Patients With Osteoarthritis of the Knee of Hip”, Merck & Co., 1997.

“A Phase III Study of the Effect of MK-0966 in the Treatment of Post Orthopedic Surgical Pain”, Merck, 1997.

“Double-Blind, Placebo Controlled, Parallel Group Comparison of the Efficacy and Safety of Morphelan TM, MS Contin”, and “Placebo with an Open label Extension in the Treatment of Osteoarthritis of the Knee and/or Hip”, Targon Corporation, 1998.

“A Randomized, Double-Blind, Efficacy and Safety Study of Oxycontin@ Tablets Administered in a Step-Down Regimen Q12H Compared to OxyContin@ Tablets in a Constant Dose Regiment Q12H after Outpatient Surgery”, Purdue Pharma. L.P., Merck, 1999.

“A Randomized, Double-Blind Comparison of the Efficacy and Safety of Hylan GF- 20 and Saline in Patients with Osteoarthritis of the Knee”, Wyeth-Ayerst, 1999.

“Double-Blind, Placebo Controlled, Dose Ranging Comparison of the Efficacy and Safety of Controlled Release Oxymorphone (Nurnorphan CR), Controlled Release Oxycodone (OxyContin~ and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip”, Endo Pharmaceuticals, 1999.

“Relative Analgesic Efficacy and Safety of Oxycodone HCL 10 mg/Ibuprofen 400 mg, Oxycodone 5 mg/Ibuprofen in Patients with Osteoarthritis of the Knee or Hip”, Merck & Co., Inc., 1997.

“A Multicenter, Open Label Extension Study to Evaluate the Long-Term Safety and Effectiveness of Numorphan CR in Patients with Chronic Pain”, Endo Pharmaceuticals, 1999.

“A Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison of the Efficacy, Upload Dose Sparing Effects, and Safety of Controlled Release Oxymorphone (Numorphan cr~ and Placebo in Patients with Post-Surgical Pain Following Total Knee Arthroplasty”, Endo Pharmaceuticals, 1999.

“A Randomized, Placebo Controlled, Parallel Group, Double-Blind Study to Evaluate the Safety and Efficacy and Rofecoxib 12.5 mg, Rofecoxib 25 mg, and Celcoxib 200 mg in Patients With Osteoarthritis of the Knee or Hip”, Merck, 200.

“A Randomized, Multicenter, Multi-Dose, Double-Blind, Double-Dummy, Parallel Group Study Comparing the Efficacy and Safety of Sustained-Release Oxycodone (Oxycodone SR) to Placebo in the Treatment of Pain Associated with Osteoarthritis”, Roxane Laboratories, 2000.

“A Randomized Placebo, and Active Comparator Controlled, Parallel Group Study of MK-0663 120 mg and NAPRELAN^TM in the Treatment of Post Orthopedic Surgical Pain”, Merck, 2000.

“A Placebo Controlled, Parallel Group, 4-Week Trial Conducted Uner Double-Blind Conditions to Assess the Efficacy and Safety of Rofecxib in Patients with Chronic Low Back Pain”, Merck, 2000.

“A Double-Blind, Placebo, Controlled Single Dose Evaluation of the Safety and Efficacy of Hydromorphone Hydrochloride Controlled-Release 24 mg Capsules in Acute Post-Operative Pain”, Purdue Pharma, 2000.

“Clinical Protocol for a Double-Blind, Placebo Controlled, Comparison, of the Narcotic Sparing Activities of Valdecoxib 20 mg, Valdecoxib 40 mg, and Placebo in Post-Orthopedic Surgical Patients”, Searle, 2000.

“Double-Blind, Randomized, Dose-Titration, Parallel-Group Comparison of the Efficacy and Safety of Extended Release Tramoadon (Tramadol ER) and Placebo in the Treatment of Osteoarthritis of the Knee”, Biovail Laboratories, Incorporated, 2000.

“Open Label Assessment of the Safety and Effectiveness of Extended Release Tramadol (Tramadol ER) in the Treatment of Chronic Non-Malignant Pain”, Biovail Laboratories, Incorporated, 2000.

“A Randomized, Double-Blind, Placebo Controlled, Parallel Group Evaluation of the Impact of OxyContin (Controlled-Release Oxycodone) vs. Usual Care (Oxycodone {Immediate/Release}/APAP) on Rehabilitation Related Health Outcomes Following Unilateral Total Knee Arthroplasty”, Purdue Pharma, 2001.

“A Multicenter, Open-Label, Multidose, 52-Week Study Designated to Assess the Safety of Propiram Fumarate (Dirame~ in the Treatment of Moderate to Severe Non-Malignant Chronic Pain”, Shire Pharmaceutical Development Inc., 2001.

“A 12 Week, Randomized, Double-Blind, Placebo Controlled, Multi-Center, Parallel Group Study to Investigate the Efficacy and Safety of ML3000 200 mg BID in Patients With Osteoarthritis (OA) of the Knee”, Forest Laboratories, 2001.

“A Single Dose Sequential Two Cohort (Open-Label Sequential Groups/Double-Blind Placebo-Controlled Parallel-Groups) Trial Designed to Evaluated the Efficacy and Safety of a Single Dose of 15, 30, 45 mg Extended-Release Hydrocodone (HCD) in Postoperative Orthopedic Patients”, Purdue Pharma 2001.

“A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Comparator (Controlled Release Oxycodone), Placebo controlled, Parallel Group Trial Assessing the Analgesic Effect of COX189 in the Treatment of Post-Surgical Pain Following Total Knee of Hip Arthroplasty”, Novartis, 2001.

“A Dose-Ranging and Arthrocentesis-Controlled Study of the Safety and Efficacy of Intra-Articular ORTHOVISC Sodium Hyaluronate Injections in Providing Symptomatic Relief of Osteoarthritis of the Knee”, Anika Therapeutics, 2001.

“A Phase III, Randomized, Multicenter, Parallel Group, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Diclofenac Potassium Softgel 25 mg or 50 mg in the Treatment of Arthroscopic Knee Surgery pain”, aaiResearch Pharmaceutical, 2007.

“A Study of the Safety of a Repeat Series of Injections of Intra-Articular ORTHOVISC Sodium Hyaluronate in Patients with Osteoarthritis of the Knee”, Anika Therapeutics, 2002.

“A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Comparison of the Safety and Efficacy of Dlrarne Propiram Fumarat (50 mg, 100 mg, and 150 mg), Oxycodone (5mg), and Placebo in the Treatment of Moderate to Severe Pain After Total Hip Replacement Surgery”, Shire Pharmaceutical Development Inc., 2002.

“A 4-Week, Randomized, Double-Blind, Placebo and Positive Controlled, Parallel Group Multicenter Study of SD-6010 in Subjects with Symptomatic Osteoarthritis of the Knee (A6171009)”, Pfizer Inc., 2004.

“A Randomized, Double-Blind, Placebo Controlled, Phase II Exploratory Study to Evaluate the Analgesic Efficacy and Tolerability of a Single Intra-Articular Injection of ALGRX 4975 in Subjects with Painful Osteoarthritis of the Knee”, AlgoRx Pharmaceuticals, 2004.

“A Multicenter, Parallel, Double-Blind, Blinded Evaluator, Randomized Comparison of the Efficacy and Safety of an alternate Viscosupplement (AVSbeta) to Depo-Medrol (Methylpednisolone acetate) in Patients with Symptomatic Osteoarthritis of the Knee”, Genzyme Corporation, 2004.

“A Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Neramexane in the Treatment of Patients with Osteoarthritis of the Knee”, Forest Research Institute, 2005.

“Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Knee Replacement: ODIXA-KNEE a Randomized, Controlled, Double-Blind, Double-Dummy Phase lib Dose Ranging Trial”, Bayer Pharmaceuticals, Inc., 2005.

“Multi-Center, Double-Blind, Randomized, Placebo Controlled, Multiple Dose Study of the Analgesic Efficacy and Safety of Acetaminophen Injections 1 G vs Placebo for Pain Following Primary Unilateral Total Hip Replacement”, Bristol-Myers Squibb, Inc., 2004.

“Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by HCl Transdermal System Versus Morphine IV Pump for Pain Management after Primary Unilateral Total Hip Replacement”, Pharmanet, Inc., 2004.

“A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Aquavan Injection Versus Midazolam HCl for Sedation in Patients Undergoing Minor Surgical Procedures” Guilford Pharmaceuticals, Inc., 2005.

“A Phase II Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of Oral Factor XA Inhibitor BMS-562247 in Subjects Undergoing Elective Total Replacement Surgery” CV 185-010, 2005.

“A Randomized, Placebo Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects after Total Knee Arthroplasty”, 4975-2-010-1, 2005.

“A Multi-Center, Randomized, Double-Blind Placebo Controlled, Parallel Design, 2-arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement Surgery”, 11694, 2005.

“RECORD 1 Study: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, Controlled Double-Blind, Randomized Study of BAY 59-7939 in Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement”, Bayer Corporation, Inc., 2005.

“RECORD 2 Study: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, Controlled Double-Blind, Randomized Study of BAY 59-7939 in Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement”, Bayer Corporation, Inc., 2005.

“IV Acetaminophen: Efficacy of a Single Dose for Postoperative Pain After Hip Arthroplasty: Subset Data Analysis of 2 Unpublished Randomized Clinical Trials”, American Journal of Therapeutics, 2014.

MEDICAL TRAINING

EDUCATION

Comeback Stories

Jeffrey C. Davis, MD

MEDICAL TRAINING

EDUCATION

Comeback Stories

Media Center